1. Introduction {#sec1-vaccines-08-00051}
===============

The control of vaccine preventable diseases (VPDs), such as measles or varicella, is a priority for healthcare systems. Outbreaks have been reported worldwide in recent years due to insufficient immunization coverage among the general population \[[@B1-vaccines-08-00051]\]. Accordingly, recent epidemiological data on VPDs in the European Union and European Economic Area (EU/EEA) demonstrate ongoing transmission in the context of insufficient vaccine coverage \[[@B1-vaccines-08-00051]\].

For instance, measles continues to be a threat in EU/EEA countries. From 1 January 2019 to 14 July 2019, 10,958 cases were reported in adults and children by the European Centre for Disease Prevention and Control \[[@B2-vaccines-08-00051],[@B3-vaccines-08-00051]\]. The highest numbers were described in France, Bulgaria, Italy, Poland, and Lithuania \[[@B4-vaccines-08-00051]\]. In fact, Italy never reached the elimination status (interruption for at least 36 months). There were 1605 cases of measles and 19 cases of rubella reported in Italy during 2019 from the 1 January to the 31 October \[[@B5-vaccines-08-00051]\].

Various studies highlighted the need to maintain protective antibody titers levels in order to reach the thresholds of herd immunity for those vaccines for which herd immunity is possible, such as measles, mumps, rubella, and varicella (MMR-V) \[[@B1-vaccines-08-00051],[@B6-vaccines-08-00051]\]. The threshold to be reached and maintained to ensure the herd immunity effect for MMR and V is 95% of vaccination coverage for 2 doses as established by the Italian National Immunization Programme (NIP) \[[@B7-vaccines-08-00051]\].

The Italian NIP is one of the most complete worldwide. However, in 2018, the vaccination coverage at 24 months of age for measles, mumps, and rubella was 93% and for varicella was 74% \[[@B8-vaccines-08-00051]\]. As a matter of fact, the herd immunity threshold for varicella in Italy was estimated around 70% according to Nardone et al \[[@B9-vaccines-08-00051]\].

Only in 2017 varicella's vaccine was introduced nationally \[[@B7-vaccines-08-00051]\]. The universal varicella vaccination was introduced progressively in some regions since 2003 \[[@B10-vaccines-08-00051]\].

Nationally, varicella's vaccination was recommended starting from 2017. In Tuscany, it was introduced since 2008 showing reduction of notification and hospitalization for varicella with a varicella coverage of 76--84% from 2010--2012 \[[@B10-vaccines-08-00051],[@B11-vaccines-08-00051],[@B12-vaccines-08-00051]\].

In 2018, 1394 children were internationally adopted in Italy. Italy is the second nation at a global level with the highest rate of international adoptions behind the United States of America \[[@B13-vaccines-08-00051]\].

The Italian NIP recommends updating of the vaccination of migrants, including internationally adopted children (IAC), as soon as possible after their arrival, in order to prevent the spread of VPDs. In fact, a large proportion of IAC are likely to be susceptible to VPDs because of suboptimal immunization \[[@B14-vaccines-08-00051],[@B15-vaccines-08-00051]\]: Children may be unvaccinated, partially vaccinated, or their immune status may be uncertain or unknown \[[@B16-vaccines-08-00051]\]. Moreover, their native country and adoptive country may have different immunization policies and schedules \[[@B17-vaccines-08-00051],[@B18-vaccines-08-00051],[@B19-vaccines-08-00051],[@B20-vaccines-08-00051]\].

Proper documentation of immunization is a worldwide problem for IAC and also for migrants and asylum seekers \[[@B21-vaccines-08-00051]\].

Few studies are available reporting the percentage of IAC with protective antibody titers for VPDs. Protective antibody titers were reported in 12--95% of IAC for measles, in 61--94% for rubella, and in 48--79% for mumps \[[@B14-vaccines-08-00051],[@B19-vaccines-08-00051],[@B20-vaccines-08-00051],[@B22-vaccines-08-00051],[@B23-vaccines-08-00051],[@B24-vaccines-08-00051],[@B25-vaccines-08-00051],[@B26-vaccines-08-00051],[@B27-vaccines-08-00051]\]. Antibody levels for varicella varied from 30--100% \[[@B14-vaccines-08-00051],[@B19-vaccines-08-00051],[@B20-vaccines-08-00051],[@B24-vaccines-08-00051],[@B25-vaccines-08-00051],[@B26-vaccines-08-00051],[@B27-vaccines-08-00051]\]. Updated information regarding the vaccination status of IAC is of paramount importance in order to support decisions regarding vaccination programs soon after arrival in the adoption country.

Therefore, the aim of the current study was to analyze measles-mumps-rubella-varicella (MMRV) vaccination documentation available and immunological status in a large population of IAC referred to a single center in Tuscany (Italy) over a 10-year period.

2. Materials and Methods {#sec2-vaccines-08-00051}
========================

2.1. Study Population {#sec2dot1-vaccines-08-00051}
---------------------

Between January 2009 and December 2018, we enrolled all the IAC consecutively referred to the Meyer Children's University Hospital by their adoptive parents, who consented to the screening evaluation. These children were assessed during the first evaluation, following the protocol recommended by the Italian national working group on migrant children (GLNIB) \[[@B19-vaccines-08-00051]\], as previously described \[[@B19-vaccines-08-00051]\] in particular focusing on immunization status.

Italian adopted children were excluded from the study. Conversely, IAC from all over the world were included if they were under 18 years of age and who had at least one serological test among measles, mumps, rubella, and varicella performed at the first evaluation. In addition, IAC whose parents did not sign consent were excluded from the study.

The study received approval by Meyer Children's University Hospital Ethics Committee, the Ethical Code Number is 15/2010. Parents who consented to their adoptive children participating in the study have signed a written informed consent.

2.2. Study Design {#sec2dot2-vaccines-08-00051}
-----------------

This is a retrospective monocentric study. For each child included in the study, the following information was collected and entered in an electronic database, following a standard operative protocol for IAC developed internationally and adopted at Meyer Children's University Hospital \[[@B19-vaccines-08-00051],[@B26-vaccines-08-00051],[@B28-vaccines-08-00051]\]. The electronic database was a secured system to protect patient information. Briefly, the following information was retrieved for the purpose of the present study: Country of origin, gender, age at first observation, vaccine documentation for MMRV, results of serological tests for measles, mumps, rubella, and varicella. At the first evaluation, all the children underwent a venepuncture and laboratory assessment including serologic tests. Staff involved for the venepuncture and laboratory assessment were appropriately trained to do so.

All the other laboratory examinations were performed in the same laboratory at the Meyer Children's University Hospital, using standardized techniques and according to manufacturers' instructions.

In particular, serology tests for measles, rubella, varicella, and mumps were performed using a chemiluminescent immunoassay (CLIA) technology (LIAISONXL System, DiaSorin, Saluggia (VC), Italy) with a definition of seropositive samples when their antibody titers were \>16.5 mIU/mL for measles, \>15 IU/mL for rubella, \>165 mIU/mL for varicella, and \>11AU/mL for mumps.

2.3. Seroprevalence of Antibody Protection against Measles, Mumps, Rubella, and Varicella {#sec2dot3-vaccines-08-00051}
-----------------------------------------------------------------------------------------

Children were subdivided according to age in five groups (\<1y, 1--4 y, 5--9 y, 10--14 y, 15--18y) and classified as protected (seropositive) or unprotected (seronegative) against each specific VPD on the basis of serotesting results. Antibody seroprevalence for each age group was calculated and expressed as a percentage.

2.4. Concordance between Vaccine Documentation and Serotesting Results {#sec2dot4-vaccines-08-00051}
----------------------------------------------------------------------

Vaccine documentation was assessed, considering the number of doses recorded and the concordance between the available documentation and serotesting results for measles, mumps, rubella, and varicella. These data were recorded and entered in tables.

2.5. Statistical Analysis {#sec2dot5-vaccines-08-00051}
-------------------------

Data were reported as median and interquartile range (IQR) or absolute numbers and percentages. Fisher exact test and Chi-square test were used to compare categorical variables, as appropriate. All statistical analyses were carried out using the SPSS (Statistical Package of Social Sciences, Chicago, IL) for Windows software program version 19.0. A *p* value \< 0.05 was considered significant.

3. Results {#sec3-vaccines-08-00051}
==========

3.1. Characteristics of the Study Population {#sec3dot1-vaccines-08-00051}
--------------------------------------------

In the decade 2009--2018, 2200 IAC from 64 countries were assessed for post-adoption screening. Of this initial group, 1927 were eligible for our study, while 273 were excluded from the evaluation because at least one serological test result was not available.

Considering serology results and/or documentation available, 1870 IAC were assessed for measles, 1868 for rubella, 631 for varicella, and 844 for mumps. Thus, 96.9% and 97% of the study population were included in the study for rubella and measles, respectively. Of the study population, 43.8% was included for mumps, whereas only 32.7% of the population was included in the study for varicella immunization status. The median age at first evaluation was 5.99 (IQR: 3.33--8.21) years, 40.1% of the children were girls (773/1927) ([Table 1](#vaccines-08-00051-t001){ref-type="table"}).

Forty percent of the IAC were adopted from Europe (777/1927), most of them were from Russia; 21.7% from Central or South America (419/1927); 19.9% were adopted from Asia (384/1927); 18% from Africa (347/1927) ([Table 1](#vaccines-08-00051-t001){ref-type="table"}). The most represented countries were Russia (458/1927, 23.8%), Colombia (146/1927, 7.6%), India (144/1927, 7.5%), and Ethiopia (125/1927, 6%). Since the most populated area of Russia is in Europe (and not in Asia), the data from Russia were entered in Europe.

Younger children came from Asia while the older were born in Americas ([Table 1](#vaccines-08-00051-t001){ref-type="table"}). Children aged 1 year or younger accounted for 2.6% of IAC, children between 1 and 4 years accounted for 39.2% of IAC, and children aged between 5 and 9 years accounted for 47.5% of IAC. Only 9.3% of the IAC were 10 to 14 years old, and older IAC belonging to the age group 15--18 years accounted for 1.3% of the population. IAC aged between 5 and 9 years represented the largest age group ([Table 2](#vaccines-08-00051-t002){ref-type="table"}).

3.2. Evaluation of the Immunological Coverage by Means of Serological Tests {#sec3dot2-vaccines-08-00051}
---------------------------------------------------------------------------

Most of the children enrolled by Meyer Children's University Hospital during the study period (2009--2018) were tested to evaluate the protective antibodies titers against measles, rubella, varicella, and mumps. Protective antibody titers were recorded in 64.9% of IAC for measles, in 60% for mumps, in 67.9% for rubella, and in 54% for varicella. Moreover, Africa was the continent with the highest percentage of unprotected children for measles (*p* \< 0.0001), rubella (*p* \< 0.0001), while IAC from Asia showed the highest percentage with unprotective antibodies for varicella (*p* \< 0.0001) ([Table 3](#vaccines-08-00051-t003){ref-type="table"}).

The large majority of children \<1 year of age were unprotected against the four VPDs investigated. Moreover, 57.7% of older children were unprotected for measles (\* *p* \< 0.001 for measles and varicella in 1--4 y vs. 15--18 y). In the age group 1--4 years, 36% of IAC were unprotected for measles, 35% for rubella, and 69% for varicella ([Figure 1](#vaccines-08-00051-f001){ref-type="fig"}).

From ages 5 and up to 14 years, we observed the highest percentage of protected IAC.Notably, almost 60% of children aged 15--18 years were unprotected for measles.

Documentation of the vaccine received in the country of origin was not always available ([Table 4](#vaccines-08-00051-t004){ref-type="table"}). In particular, a discrepancy between documentation indicating previous vaccinations and unprotective (seronegative) antibody titers was evidenced in 25.6% of the children for measles, 24.9% for rubella, 53.3% for varicella, and 25% for mumps ([Table 4](#vaccines-08-00051-t004){ref-type="table"}).

By evaluating the serological results according to documentation records and age groups, it is evident that under 1 year of age there was a high percentage of IAC without serological protection: 87.75% for measles, 82.35% for rubella, and 72.73% for varicella ([Figure 1](#vaccines-08-00051-f001){ref-type="fig"}).

The discrepancy between serological results and vaccine documentation was reported in Africa from 49% to 54% depending on the disease considered. For Americas, the discrepancy varied from 47% to 70%. The discrepancy varied for Asia from 35% to 42% and for Europe from 33% to 58% ([Table 5](#vaccines-08-00051-t005){ref-type="table"}).

Considering age groups, discrepancies were observed from 12% to 27% for IAC \<1 year of age, from 33% to 38% for IAC from 1 to 4 years of age, from 42% to 64% for IAC from 5 to 9 years of age, from 32% to 78% for IAC from 10 to 14 years of age, and for adolescences 15--18 years of age from 50% to 73%.

According to documentation of vaccinations, except for mumps vaccination records, most children did not receive any dose of vaccine ([Table 6](#vaccines-08-00051-t006){ref-type="table"}). Most IAC \<1 year of age had no documentation of vaccination. More often IAC from 1--4 and from 5--9 age groups had some documentation of previous vaccination. Particularly, children in the 5--9 age group were those who had more frequently recorded the second dose.

4. Discussion {#sec4-vaccines-08-00051}
=============

In the current study we analyzed the measles-mumps-rubella-varicella (MMRV) vaccination status and serological data available in a large population of IAC referred to a single center in Tuscany (Italy) over a 10-year period. To our knowledge, this is one of the most numerous studies including data from more than 1900 IAC collected over a 10-year period. A large proportion of children resulted seronegative toward measles (35.1%), rubella (32.1%), varicella (45.9%), and mumps (40%). These figures are more pronounced considering African children for measles and rubella (46.3% and 41.2%, respectively) and Asian children for varicella (60%). As expected, children \<1 year of age were more commonly unprotected (72--88%), as the first dose of MMR-V vaccine is recommended between 12 and 15 months of age. The second dose is recommended during childhood. The minimum interval between first dose and second dose is 4 weeks. In Italy the second dose is recommended at 5--6 years of age. Age group 1--4 years may have only received 1 dose and would not be fully protected. Our results show that in the age group 1--4 years, a percentage between 35--69% of children were unprotected ([Figure 1](#vaccines-08-00051-f001){ref-type="fig"}) particularly for measles, rubella, and varicella. From ages 5 and up to 14 years, we observed the highest percentage of protected IAC. Notably, almost 60% of children aged 15--18 years were unprotected for measles, representing an age group which should be considered particularly at high risk. It shouldn't be taken for granted that adolescents have already received vaccination against MMRV or have already acquired the infection.

Several studies assessing the proportion of children (IAC and migrants) with protective antibody titers against different VPDs are available. These studies reported a high variability of antibody protection rates. In particular, protective antibody titers were reported in a range of 12--95% for measles, 61--94% for rubella, 48--79% for mumps, and 30--100% for varicella. Our data/results were in accordance with the results of previous studies \[[@B6-vaccines-08-00051],[@B11-vaccines-08-00051],[@B14-vaccines-08-00051],[@B15-vaccines-08-00051],[@B16-vaccines-08-00051],[@B19-vaccines-08-00051],[@B20-vaccines-08-00051],[@B21-vaccines-08-00051],[@B22-vaccines-08-00051],[@B23-vaccines-08-00051],[@B24-vaccines-08-00051],[@B25-vaccines-08-00051],[@B26-vaccines-08-00051],[@B27-vaccines-08-00051],[@B28-vaccines-08-00051],[@B29-vaccines-08-00051],[@B30-vaccines-08-00051]\].

The written documentation of the IAC may not accurately reflect the immunization status \[[@B24-vaccines-08-00051],[@B29-vaccines-08-00051]\].

The lack of vaccine documentation reliability has been reported in literature and numerous studies have correlated this unreliability with no protection or under-immunization \[[@B14-vaccines-08-00051],[@B20-vaccines-08-00051],[@B22-vaccines-08-00051],[@B30-vaccines-08-00051],[@B31-vaccines-08-00051],[@B32-vaccines-08-00051]\]. Our data underline the poor reliability of vaccine documentation, when available: Discrepancies between serological test results and vaccine documentation were observed in about one-quarter of IAC for MMR and more than half the children for varicella.

These studies report a variable documentation reliability in the range of 62--83% for measles, 38--86% for rubella, 55--75% for mumps, and 47--91% for varicella. In particular, in the most recent study conducted by Giordano et al., the reliability of the documentation for measles, mumps, rubella, and hepatitis B were assessed \[[@B14-vaccines-08-00051]\]. This study showed a concordance between protective antibody titers and written documentation stating the vaccinations which had been carried out in the country of origin. The concordance was 78% for measles, 65.2% for mumps, 83.6% for rubella, and 71.2% for hepatitis B \[[@B14-vaccines-08-00051]\].

According to the literature, IAC's place of birth has been described to be related with the reliability of immunization records. For example, African and Central American IAC had a lack of vaccine documentation compared with Eastern European and Asian IAC \[[@B32-vaccines-08-00051]\]. Some authors have reported that certificates were written with the same pencil, reported in the same date of consecutive months, or even dated before the child's birth \[[@B22-vaccines-08-00051]\]. Some other obstacles identified when reviewing the immunization records were translation issues and misinterpretation of written reported brand name of the vaccine.

Any vaccines the children may have received could be ineffective due to suboptimal storage and transport or because they were administered after the expiration date \[[@B16-vaccines-08-00051],[@B17-vaccines-08-00051]\]. IAC are often malnourished and have severe co-infections or immunodeficiencies and these increase their risk of immunization failure \[[@B19-vaccines-08-00051],[@B20-vaccines-08-00051]\].

Despite the existence of vaccination records, these can be unreliable and justify the importance of serology test promptly after the arrival of IAC.

Our study has several limitations. During the 10-year study period some investigations included in the screening protocol changed, and some tests were not performed in the whole population: In fact, the large majority of the children referred to Meyer Children's University Hospital and included in the study were evaluated as per protocol, but for some variables some data were missing, possibly due to the physicians' incomplete adherence to the screening protocol or to an incomplete collection of data in medical records. Indeed, it must be considered that our center was able to recruit only a part of all the adopted children arriving in Tuscany, as some parents may have consulted their primary care pediatrician or no one at all. Lastly, there is no absolute association between being unprotected and not having protective antibody titers, since immune response to vaccines is complex and relies on different immunologic mechanisms, which are not all explored by serology testing \[[@B33-vaccines-08-00051]\].

5. Conclusions {#sec5-vaccines-08-00051}
==============

Our data underline the importance of a rapid, careful, and complete assessment of immunization status in IAC. Many factors, such as lack of public health infrastructure or maintenance of the cold chain for the storage of the vaccines or malnutrition especially in low- and middle-income countries, influence the serological pattern of these children. This study highlighted that more than half of the newly arrived IAC were unprotected against MMRV. Notably, even if vaccination documentation of the country of origin was available, this was not always reliable: a quarter of the IAC were not protected in the current study. Our data suggest that vaccination status and serological assessment should be promptly performed on all IAC after their arrival in order to prevent outbreaks of VPDs.
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vaccines-08-00051-t001_Table 1

###### 

Characteristics of the study population by continent of origin, gender, and median age.

                     Africa        Americas      Asia          Europe        Total
  ------------------ ------------- ------------- ------------- ------------- --------------
  Population (*n*)   347 (18%)     419 (21.7%)   384 (19.9%)   777 (40.3%)   1927 (100%)
  Median age (y)     5.19          7.37          4.81          6.19          5.99
  IQR                2.66--6.79    5.30--9.34    2.01--7.06    3.73--8.26    3.33--8.21
  Females (*n*)      145 (41.8%)   193 (46.1%)   175 (45.6%)   260 (33.5%)   773 (40.1%)
  Males (*n*)        202 (58.2%)   226 (53.9%)   209 (54.4%)   517 (66.5%)   1154 (59.9%)

vaccines-08-00051-t002_Table 2

###### 

Continent of origin of the internationally adopted children (IAC) referred to Meyer Children's University Hospital, Florence, in the period (2009--2018), by age group (%).

  Age Group Year   Africa % (*n* = 347)   Americas % (*n* = 419)   Asia % (*n* = 384)   Europe % (*n* = 777)   Total % (*n* = 1927)
  ---------------- ---------------------- ------------------------ -------------------- ---------------------- ----------------------
  \<1              6.3                    0.2                      6.3                  0.5                    2.6
  1--4             47.6                   21                       48.2                 40.8                   39.2
  5--9             38.6                   62.8                     41.1                 46.3                   47.5
  10--14           5.5                    14.6                     3.6                  11.1                   9.3
  15--18           2                      1.4                      0.8                  1.3                    1.3
  total            18%                    21.7%                    19.9%                40.3%                  100%

vaccines-08-00051-t003_Table 3

###### 

Percentage of children in the study with unprotective antibody titers (seronegative) against measles, rubella, varicella, and mumps, by continent of origin.

                      UNPROTECTED/Total Number of Children for Each Disease   Africa (*n* = 347)   Americas (*n* = 419)   Asia (*n* = 384)   Europe (*n* = 777)
  ------------------- ------------------------------------------------------- -------------------- ---------------------- ------------------ --------------------
  Measles n/N (%)     657/1870 (35.1%)                                        156/337(46.3%)       147/409 (35.9%)        159/377 (42.2%)    195/747 (26.1%)
  Rubella n/N (%)     600/1868 (32.1%)                                        139/337 (41.3%)      89/408 (21.8%)         136/373 (36.5%)    236/750 (31.5%)
  Varicella n/N (%)   290/631 (46.0%)                                         63/120 (52.5%)       42/134 (31.3%)         102/170 (60.0%)    83/207 (40.1%)
  Mumps n/N (%)       10/25 (40.0%)                                           2/15 (13.3%)         0/193 (0.0%)           5/122 (4.1%)       3/514 (0.6%)

vaccines-08-00051-t004_Table 4

###### 

Comparison between documentation recorded and serological tests performed in Italy.

  VPD         Immunization Status According to Documentation *n* (%)   Immunization Status According to Serological Test *n* (%)   Total               
  ----------- -------------------------------------------------------- ----------------------------------------------------------- ------------- ----- --------------
                                                                       Protected                                                   Unprotected         
  Measles     Recorded                                                 717 (74.4)                                                  247 (25.6)    964   *p* \< 0.001
              Not recorded                                             496 (54.7)                                                  410 (45.3)    906   
  Rubella     Recorded                                                 674 (75.1)                                                  223 (24.9)    897   *p* \< 0.001
              Not recorded                                             594 (61.2)                                                  377 (38.8)    971   
  Varicella   Recorded                                                 35 (46.7)                                                   40 (53.3)     75    *p* = 0.172
              Not Recorded                                             306 (55.0)                                                  250 (45.0)    556   
  Mumps       Recorded                                                 6 (75.0)                                                    2 (25.0)      8     *p* = 0.294
              Not Recorded                                             9 (52.9)                                                    8 (47.1)      17    

vaccines-08-00051-t005_Table 5

###### 

Number and percentage of IAC with concordance and discordance between documentation records and serological results by continent of origin and age group.

  Continent    Concordance/Discordance   Measles   Rubella   Varicella                  
  ------------ ------------------------- --------- --------- ----------- -------- ----- --------
  Africa       Concordance               168       49.85%    154         45.70%   61    50.83%
               Discordance               169       50.15%    183         54.30%   59    49.17%
  Total                                  337                 337                  120   
  Americas     Concordance               214       52.32%    212         51.96%   40    29.85%
               Discordance               195       47.68%    196         48.04%   94    70.15%
  Total                                  409                 408                  134   
  Asia         Concordance               245       64.99%    234         62.73%   97    57.06%
               Discordance               132       35.01%    139         37.27%   73    42.94%
  Total                                  377                 373                  170   
  Europe       Concordance               500       66.93%    451         60.13%   87    42.03%
               Discordance               247       33.07%    299         39.87%   120   57.97%
  Total                                  747                 750                  207   
  Age group                                                                             
  \<1 yrs      Concordance               43        87.76%    41          80.39%   8     72.73%
               Discordance               6         12.24%    10          19.61%   3     27.27%
  Total                                  49                  51                   11    
  1--4 yrs     Concordance               455       62.24%    473         64.97%   143   67.14%
               Discordance               276       37.76%    255         35.03%   70    32.86%
  Total                                  731                 728                  213   
  5--9 yrs     Concordance               514       58.08%    444         50.17%   111   36.27%
               Discordance               371       41.92%    441         49.83%   195   63.73%
  Total                                  885                 885                  306   
  10--14 yrs   Concordance               102       56.98%    88          49.44%   17    21.79%
               Discordance               57        31.84%    90          50.56%   61    78.21%
  Total                                  179                 178                  78    
  15--18 yrs   Concordance               13        50.00%    5           19.23%   6     26.09%
               Discordance               13        50.00%    21          80.77%   17    73.91%
  Total                                  26                  26                   23    

Note: Concordance = seropositive IAC with documentation of previous vaccination and seronegative with unrecorded vaccination. Discordance = seropositive IAC despite the absence of vaccination records and seronegative while the documentation attests the vaccination as received.

vaccines-08-00051-t006_Table 6

###### 

Number of doses documented for IAC by age groups.

                          Age Group   0 Dose   1 Dose   2 Doses
  ----------------------- ----------- -------- -------- ---------
  Measles (*n* = 1870)    \<1 y       45       4        0
  1--4 y                  368         318      45       
  5--9 y                  446         246      193      
  10--14 y                93          33       53       
  15--18 y                20          3        3        
  Rubella (*n* = 1868)    \<1 y       50       1        0
  1--4 y                  407         296      25       
  5--9 y                  455         258      172      
  10--14 y                102         32       44       
  15--18 y                23          2        1        
  Varicella (*n* = 631)   \<1 y       11       0        0
  1--4 y                  186         23       4        
  5--9 y                  273         25       8        
  10--14 y                75          2        1        
  15--18 y                23          0        0        
  Mumps (*n* = 844)       \<1 y       3        0        0
  1--4 y                  6           286      23       
  5--9 y                  7           258      178      
  10--14 y                1           33       45       
  15--18 y                0           3        1        
